THE USE OF SUNITINIB IN PANCREATIC NEUROENDOCRINE TUMORS: EXPERIENCE OF THE DEPARTMENT OF CHEMOTHERAPY FSBI RORC N.A. N.N. BLOKHIN OF RMH


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In order to evaluate the efficacy and toxicity of sunitinib in previously treated 19 patients with neuroendocrine tumors (NETs) of the pancreas, the safety profile with pancreatic NETs G1, G2 was assessed. Stabilization was observed in the majority (78.6%) of patients, the progression was registered in 1 (7.1%) patient. Duration of stabilization (median) was 395 days (95% CI, 162-518 days). The results showed that the efficacy of treatment with sunitinib corresponds to the results presented in the world literature. Identified adverse events correlate with the known toxicity profile of the drug.

Full Text

Restricted Access

About the authors

A. S Odintsova

Email: odincova.anastas@mail.ru
FSBI RORC n.a. N.N. Blokhin of RMH PhD, Oncologist at the Department of Chemotherapy Moscow

V. A Gorbunova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

N. F Orel

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

A. A Markovich

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

A. E Kuzminov

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

S. A Polozkova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

G. S Emelyanova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

A. A Kuznetsova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

References

  1. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. 2003;9:327-37.
  2. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. J. Clin. Oncol. 2006;24(1): 25-35.
  3. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patents with metastatic renal cell carcinoma. J. Clin. Oncol. 2006;24(1): 16-24.
  4. Motzer R.J., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferonalfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proceedings ASCO 2006, abstr. LBA3.
  5. Rini B.I., et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proceedings ASCO 2006, abstr. 4522.
  6. Demetri G.D., et al. SU 11248, a multitargeted tyrosine kinase inhibitor, can overcome imatinib -resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor. Proceedings ASCO 2004, abstr. 3001.
  7. Morgan J.A., et al. Patients with Imatinib-mesylate-resistant GIST exhibit durable responses to Sunitinib malate (SU11248). 17th ICACT, 2008; poster session.
  8. Demetri G.D., et al. Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. Advances in the Treatment of Esophageal and Gastric Cancers, abstr. 8.
  9. Beaumont J.L., et al. Efficacy and Patient-Reported Outcomes of Sunitinib Malate (SU11248) in Three Phase II Trials in advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor. 17th ICACT, 2008; poster session.
  10. Miller K.D., et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proceedings ASCO 2005, abstr. 563.
  11. Raymond E., Faivre S., Hammel P., Ruszniewski P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol. 2009;4(4):253-54.
  12. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011;364(6):501-13.
  13. Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008;26(20):3403-10.
  14. Frilling A., Akerström G., Falconi M., Pavel M., Ramos J., Kidd M., Modlin I.M. Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat Cancer. 2012;19:163-85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies